These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17361511)

  • 1. As drug payment model changes, confusion grows among insurers.
    Sipkoff M
    Manag Care; 2007 Feb; 16(2):56-9. PubMed ID: 17361511
    [No Abstract]   [Full Text] [Related]  

  • 2. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme.
    Sainsbury P
    Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920
    [No Abstract]   [Full Text] [Related]  

  • 3. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
    Hamilton C; Lokuge B; Denniss R
    Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharma APMs: Can the Industry Learn To Play Well With Others?
    Alston M; Pyenson B
    Manag Care; 2018 Sep; 27(9):31-32. PubMed ID: 30216160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insurers' strategies for managing the use and cost of biopharmaceuticals.
    Robinson JC
    Health Aff (Millwood); 2006; 25(5):1205-17. PubMed ID: 16966716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Price pressure. As the number of costly specialty drugs grows, insurers and providers push for more reasonable alternatives.
    Evans M
    Mod Healthc; 2013 Jan; 43(4):6-7, 16, 1. PubMed ID: 23488108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacy benefit management: the right Rx?
    Etheredge L
    Res Agenda Brief; 1995 Apr; (1):1-11. PubMed ID: 12856664
    [No Abstract]   [Full Text] [Related]  

  • 8. Growing pains. Insurers and PbMs want in on 340B savings.
    Lee J
    Mod Healthc; 2012 Mar; 42(11):10. PubMed ID: 22462315
    [No Abstract]   [Full Text] [Related]  

  • 9. Lowering patient drug acquisition costs to improve health outcomes and costs.
    Mahoney JJ
    Manag Care Interface; 2006 Apr; 19(4):13. PubMed ID: 16689022
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug firms and insurers move to center stage in the cost debate.
    Goozner M
    Mod Healthc; 2015 Feb; 45(8):26. PubMed ID: 25823208
    [No Abstract]   [Full Text] [Related]  

  • 11. PDP drug costs are higher than employer plans.
    Manag Care; 2008 May; 17(5):50. PubMed ID: 18567470
    [No Abstract]   [Full Text] [Related]  

  • 12. Insurers, PBMs continue to fight for bigger, better drug price discounts.
    Herman B
    Mod Healthc; 2015 Aug; 45(31):14. PubMed ID: 26540771
    [No Abstract]   [Full Text] [Related]  

  • 13. Pricing in the Market for Anticancer Drugs.
    Howard DH; Bach PB; Berndt ER; Conti RM
    J Econ Perspect; 2015; 29(1):139-62. PubMed ID: 28441702
    [No Abstract]   [Full Text] [Related]  

  • 14. PBMs agree to disclose what they pay for drugs.
    Sipkoff M
    Manag Care; 2007 Nov; 16(11):19-20. PubMed ID: 18092549
    [No Abstract]   [Full Text] [Related]  

  • 15. Unlock savings through innovative pharmacy benefit design.
    Edlin M
    AHIP Cover; 2005; 46(4):14-20. PubMed ID: 16149655
    [No Abstract]   [Full Text] [Related]  

  • 16. PBMs raise the curtain.
    Sipkoff M
    Manag Care; 2006 Sep; 15(9):38-40, 43. PubMed ID: 17036937
    [No Abstract]   [Full Text] [Related]  

  • 17. The formulary files. PBMs report increase in drug margins.
    Manag Care; 2006 Jan; 15(1):59. PubMed ID: 16502778
    [No Abstract]   [Full Text] [Related]  

  • 18. [TLV meets criticism: costs of antihypertensive agents can and should be reduced].
    Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D
    Lakartidningen; 2008 Sep 17-23; 105(38):2592-3. PubMed ID: 18846865
    [No Abstract]   [Full Text] [Related]  

  • 19. Congress has its brain on drug benefits.
    Birnbaum JH
    Fortune; 2003 Jan; 147(1):178. PubMed ID: 12602124
    [No Abstract]   [Full Text] [Related]  

  • 20. Crossing boundaries. Big Pharma stalls discounted Maine Rx drug program.
    White C
    Revolution (Oakl); 2002; 3(6):9. PubMed ID: 12599702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.